Table.
Characteristics of Participants from NHLBI BioLINCC in Earlier and Later Time Periodsa
| Overall | Earlier Era CHD Casesb | No CHDb | Overall | Later Era CHD Casesb | No CHDb | |
|---|---|---|---|---|---|---|
| N | 14009c | 1428 | 12581 | 14009c | 1317 | 12692 |
| Age | 60.4 (8.2) | 64.4 (8.4) | 60.0 (8.1) | 60.6 (8.1) | 65.0 (7.4) | 60.1 (8.1) |
| Sex (female) | 56.0 | 42.2 | 57.6 | 56.0 | 45.6 | 57.1 |
| Black/AA | 15.4 | 15.9 | 15.3 | 15.4 | 14.7 | 15.5 |
| SBP (mmHg) | 127 (20) | 137(21) | 126 (20) | 125 (19) | 134 (21) | 125 (19) |
| SBP ≥140 mmHg | 24.1 | 41.7 | 22.1 | 21.0d | 35.9 | 19.5 |
| On BP treatment | 27.2 | 42.6 | 25.4 | 31.6d | 47.3 | 30.0 |
| Diabetese | 10.4 | 22.4 | 9.0 | 11.0 | 18.5 | 10.2 |
| Smokerf | 21.8 | 25.4 | 21.4 | 14.3d | 18.8 | 13.8 |
| HDL-C (mg/dL) | 53 (17) | 49 (15) | 54 (17) | 52 (16) | 49 (15) | 52 (16) |
| HDL-C <50 mg/dL | 47.0 | 58.4 | 45.7 | 51.0d | 59.1 | 50.2 |
| Total-C (mg/dL) | 217 (40) | 220 (42) | 217 (40) | 200 (36) | 206 (39) | 200 (36) |
| Total-C ≥200 mg/dL | 65.4 | 68.3 | 65.1 | 48.9d | 55.7 | 48.2 |
| Total:HDL-C ratio | 4.4 (1.5) | 4.8 (1.5) | 4.4 (1.5) | 4.2 (1.3) | 4.5 (1.4) | 4.2 (1.3) |
| Total:HDL-C ratio ≥4.0 | 55.8 | 68.2 | 54.3 | 51.4d | 61.7 | 50.3 |
| On LL treatment | 2.9 | 3.4 | 2.8 | 11.3d | 13.7 | 11.1 |
Abbreviations: AA, African American; BioLINCC, Biologic Specimen and Data Repository Information Coordinating Center; CHD, coronary heart disease; HDL-C, high-density lipoprotein cholesterol; NHLBI, National Heart, Lung, and Blood Institute; on BP treatment, on blood pressure medication(s); on LL treatment, on lipid-lowering medication(s); SBP, systolic blood pressure; total-C, total cholesterol; total:HDL-C ratio, total-to-high-density lipoprotein cholesterol ratio
Mean and standard deviation for continuous variables, % for categorical variables; NHLBI BioLINCC cohorts contributing data include:
Framingham Heart Study Original Cohort (FHS Original, examinations in 1983–1985 and 1997–1999): n=522 earlier, 48 later
Framingham Heart Study Offspring Cohort (FHS Offspring, examinations in 1983–1987 and 1998–2001): n=1935 earlier, 1808 later
Atherosclerosis Risk in Communities (ARIC, examinations in 1987–1989 and 1996–1998): n=8145 earlier, 6696 later
Cardiovascular Health Study (CHS, examinations in 1989–1990 and 1997–1998): n=3407 earlier, 1901 later
Multi-Ethnic Study of Atherosclerosis (MESA, examination in 2000–2002): n=3556 later
All adults free of cardiovascular disease at baseline, these are characteristics of adults who do and do not develop CHD in follow-up.
4833 individuals in the earlier and 6080 in the later era were excluded due to no matches
Comparison of prevalence in the overall group in the earlier and later eras, *p<0.001, otherwise p>0.05
Diabetes defined as fasting glucose at or above 126 mg/dL (random glucose above 200 mg/dL in FHS Original Cohort) or on diabetes treatment.
Smoker defined as current or within the past year.